
Cassel Salpeter & Co.’s Q3 healthcare update points to disrupted NIH grant processing, FDA attrition, and tariffs as pressures on drug development and early-stage financing.
Bert Spilker has been involved in clinical trials for 30 years. He?s written books, founded companies, and helped steer regulatory agencies. Now he wants to change how drugs are developed.
about 24 years ago
IRBs in the Spotlightabout 24 years ago
Building a Home Networkabout 24 years ago
A Dream Unfulfilled: European Clinical Trials Rules Are Not Workingabout 24 years ago
Learn Before You Leapabout 24 years ago
A Faithful Subjectabout 24 years ago
Using IVRS in Clinical Trial Managementabout 24 years ago
The Virtual Training Processabout 24 years ago
Adding Centers to Boost Subject Accrual





